Acorn Capital Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Acorn Capital Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-405,237	Closed	-$977K	–	23
2025 Q4	$977K	Hold	405,237	–	–	0.33%	20
2025 Q3	$733K	Hold	405,237	–	–	0.37%	19
2025 Q2	$482K	Hold	405,237	–	–	0.32%	20
2025 Q1	$823K	Hold	405,237	–	–	0.55%	22
2024 Q4	$2.44M	Buy	+405,237	New	+$2.94M	1.31%	18

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acorn Capital Advisors's ACRV Position: Q1 2026 in Review

Acorn Capital Advisors sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 405,237 shares — an estimated $977K sold.

Acorn Capital Advisors first reported a position in ACRV in Q4 2024 and held it in 5 quarters. The position peaked at $2.44M in Q4 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Acorn Capital Advisors reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
Acorn Capital Advisors sold 405,237 Acrivon Therapeutics shares in Q1 2026, an estimated $977K.
Acorn Capital Advisors first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 5 quarters.
Acorn Capital Advisors's Acrivon Therapeutics position peaked at $2.44M in Q4 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.